THE Pharmaceutical Benefits
Advisory Committee has released
its July recommendations.
These include that all docetaxel
and paclitaxel products be changed
from Authority required to
unrestricted listings.
The Committee also
recommended that the listing of
strontium be amended so that
it was placed in a second line
setting where the patient was
unable to use other osteoporosis
treatments due to contraindication
or intolerance, following the
addition of a black box on product
information (PD 04 Apr), and so
that returning it to a telephone
Authority would be appropriate.
The Committee also
recommended that MS treatment
alemtuzumab be listed as Authority
Required Section 100.
CLICK HERE to read more.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Aug 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.